Plug Arterial Closure System (PACS, 7F) (PACS 7F)

Cordis

Status and phase

Completed

Phase 2

Conditions

Angioplasty, Transluminal, Percutaneous Coronary

Coronary Arteriosclerosis

Treatments

Device: Vascular access site closure (7F Ensure)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00533156

EMI 07-02

Details and patient eligibility

About

The purpose of this study is to assess the safety and feasibility of the 7F Ensure Medical Vascular Closure Devices to facilitate hemostasis in patients undergoing diagnostic or interventional coronary procedures using a standard 7F introducer sheath.

Full description

Achieving hemostasis at the arterial puncture site after percutaneous cardiac catheterization is a potential cause of bleeding, hematomas, pseudoaneurysms, and various other vascular complications. Hemostasis at the femoral artery access site after diagnostic or interventional procedures is typically achieved using either manual compression or the deployment of a vascular closure device. Manual compression is time consuming for the health-care provider, and painful for the patient. In addition, prolonged periods of immobilization and bed rest may be required. Vascular closure devices have been developed to avoid manual compression, shorten bed rest, and allow earlier ambulation.

The Ensure Medical Vascular Closure device (VCD) is intended for femoral artery puncture site closure in patients who have undergone coronary catheterizations using a standard 7F introducer sheath. The device is comprised of a bio-absorbable plug and a plug delivery system. The plug delivery system is designed to position the bio-absorbable plug to the extravascular surface of the femoral artery access site, facilitating a hemostasis response. The Ensure Medical VCD has been studied in a prior feasibility trial of 149 patients utilizing a 6F introducer sheath, which demonstrated that: (1) the device could be used to successfully obtain rapid hemostasis and early ambulation in patients undergoing catheterization procedures; and (2) the low incidence and relatively minor nature of the observed closure related complications suggests that the device is safe for its intended purpose.

Enrollment

30 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Scheduled for a coronary diagnostic or interventional procedure
Able to undergo emergent vascular surgery if a complication requires it
7F arterial puncture located in the common femoral artery
Femoral artery has a lumen diameter of at least 5 mm

Exclusion criteria

Arterial puncture in the femoral artery of both legs
Prior target artery closure with any vascular closure device, or closure with manual compression within 30 days prior to catheterization
Patients who bruise or bleed easily or with a history of significant bleeding or platelet disorders
Acute ST-elevation myocardial infarction within 48 hours prior to catheterization
Uncontrolled hypertension at time of vessel closure
Elevated Activated Clotting Time at time of vessel closure
Ineligible for in-catheterization lab introducer sheath removal
Concurrent participation in another investigational device or drug trial
Thrombolytic therapy, bivalirudin, other thrombin-specific anticoagulants, or low molecular weight heparin within 24 hours prior to catheterization
Preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to femoral artery closure
Prior femoral vascular surgery or vascular graft in region of access site
Femoral artery is tortuous or requires an introducer sheath longer than 11 cm
Fluoroscopically visible calcium, atherosclerotic disease, or stent within 1 cm of the puncture site that would interfere with the operation of the experimental device
Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture
Antegrade vascular puncture
Body Mass Index over 40 kg/m2
Symptomatic leg ischemia in the target limb including severe claudication or weak/absent pulse
Femoral artery diameter stenosis exceeding 50%
Pre-existing severe non-cardiac systemic disease or terminal illness
Planned arterial access at the same access site within 30 days of catheterization
Extended hospitalization (e.g. CABG surgery)
Pre-existing systemic or cutaneous infection
Prior use of an intra-aortic balloon pump through the arterial access site
Cardiogenic shock during or immediately following the catheterization
Patient is unable to ambulate at baseline
Patient is known or suspected to be pregnant or is lactating
Patient is unavailable for follow-up
Any angiographic or clinical evidence that the physician feels would place the patient at increased risk with the use of the experimental device